Apontis Pharma : Earnings Call 2023 Presentation

APONTIS PHARMA	2024	3.0 Growth
The specialized leader for Single Pill Combinations
Earnings Call 2023	2023
March, 28th 2024	Transformation

2021

2.0 IPO

2018	1.0 Foundation

1 · 2024

Disclaimer

The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by APONTIS PHARMA AG (the "Company"), is not an offer to sell any securities or an invitation to purchase securities or the solicitation of an offer to buy securities. This Presentation is not an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended.

The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company. The information in the Presentation is subject to updating, completion, revision and verification.

No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law and regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of its respective directors, officers, partners, employees, agents, affiliates, representatives or advisers, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation.

None of the Company, its affiliates and advisers, agents and/or any other party undertakes or is under any duty to update the Presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation.

The Presentation includes statements that are, or may be deemed to be, forward-looking statements. These statements are based on the current views, expectations and assumptions of the management of the Company and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those described in such statements due to, among other things, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations and competition from other companies, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, affecting the Company and other factors. The Company does not assume any obligations to update any forward- looking statements. The Presentation includes statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Company's business and markets. Unless otherwise indicated, such information is based on analysis by the Company of multiple sources, including certain studies commissioned from third parties (the "Market Reports"). The Market Reports may include and be based on, amongst other things, information obtained from primary interviews and field visits conducted by third parties with industry experts and participants, third parties' secondary market research and internal financial and operational information supplied by, or on behalf of, the Company, as well as information obtained from (i) data providers; (ii) industry associations and country organizations; and (iii) publicly available information from other sources, such as information publicly released by the Company's competitors. To the extent available, the industry, market and competitive position data contained in the Presentation has come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained in them have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in the Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the markets in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in the Presentation. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of the matters described in the Presentation. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and, to the extent that they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

The distribution of this Presentation in certain jurisdictions is restricted by law. Therefore, it must not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. All trademarks remain the property of their respective owners. By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you will not forward the Presentation to any other person or reproduce or publish this document, in whole or in part, for any purpose; and (ii) you have read and agree to comply with the contents of this notice.

2 · 2024

Executive Team

Thomas Milz	Bruno Wohlschlegel	Thomas Zimmermann
Chief Product Officer	Chief Executive Officer (from 1 Sept 2023)	Chief Finance Officer
•	Business Development	•	Strategy	•	Finance
•	Market Access	•	Marketing & Sales	•	Investor Relations
•	Medical & Regulatory Affairs	•	Human Resources	•	IT
•	Product Development	•	Supply Chain	•	Compliance

"Drug non-compliance is a stealth epidemic exacting a heavy toll on the healthcare system - our broad portfolio of Single Pill Combinations is designed to help tackle this epidemic."

3 · 2024

APONTIS PHARMA - 2023 Results

A negative result that calls for a turnaround

2023

• Lower sales and negative EBITDA due to one-time effects and lack of market impact
• Accelerated growth (Atorimib) & cost discipline in Q4 2023 start off trend reversal

Status Quo and Outlook

• Restructuring successfully completed
• New Go-To-Market Model started ahead of plan (March 1st)
• Focus on core business: Single Pill portfolio set up for profitable growth in 2024
• Additional growth opportunities identified

4 · 8 March, 2023

APONTIS 3.0

Promising value proposition and strong engagement

New Go-To-Market Model to leverage growth potential

APONTIS 2. 0	APONTIS 3.0		Outcome
• No lifecycle approach to grow			• Faster launch uptake and
	specific Single Pills	• Specific Single Pill campaigns		lifecycle maximization for
					established brands
•	Additional communication	•	Integrated Multichannel
	channels are underdeveloped		communication	•	Strong increase of share of
	and not integrated				voice
		• Sales force focus on most
• Post-pandemic loss of call		valuable HCPs/centers	•	Higher contact rate/HCP with
	capacity (-20%)				stronger growth rates
		• Up-to-date commercial
• Very broad customer base		excellence methods	•	High-efficiency gains and fast
	leads to sub-optimal frequency				and flexible response to
	of high-potential customers	•	Leverage payer's collaboration		opportunities and challenges
			and medical peer groups
•	Sales Force excellence with			•	Impactful additional trigger for
	room for improvement	•	Learning organisation		Single Pill prescription

5 · 2024

Go-To-MarketRe-design

Profitability in 2024 and sustained profitable growth ´24+

Grow Bottom Line

Grow Top Line

Redesign for Efficacy

Focus on high-value accounts/customers

APONTIS 2.0

static modelImplement Multichannel approach

Shape for Efficiency

Reduce costs by downsizing organisation according to new model

APONTIS

3.0

Scalable model for profitable growth in

• Germany
• Europe+ 27ff

6 · 2024

APONTIS PHARMA 3.0

Flexible Resource Allocation based on growth opportunities & Market development

Direct Marketing

		HCP
		Co-Development
		P-2-P
Headcount:	185	 110
Salesforce new:	65	(50/10/5)
Restructuring costs:	5.6 M€ (estimate: 5-8 M€)

Savings (annualized): 6.5 M€ (estimate: 6-7M€)

Sales Force

Sales Force

7 · 2024

Market Access

Medical

Marketing

Solid base and future opportunities

Opportunities for future growth

Existing business

APONTIS PHARMA

Licenses /IP	Go-To-Market	Cooperation	Medical Standard
	Model
Internationalization	scalable	Opportunities to boost	Single Pill combinations
2027 ff		EBIT / finance growth	adopted as standard

Single Pill		Portfolio expansion	Organisation	Cost structure
Core business
growing		20 in 2025	Go2M up & running	lean	
	Risk reduction 	

8 · 2024

Financials FY 2023

FY 2023 at a glance

Impact of contract end Jalra/Icandra and tender/supply situation Atorimib

Financial Highlights FY 2023
Single Pill Revenues	Total Revenues	EBITDA
		(before restructuring)
EURm 25.6	EURm 37.0	EURm -13.3
		(EURm -7.7)
(-30%)	(-34 %)	(PY EURm 5.6)

Note: Rounding differences may occur. Source: Company data; audited financials.

10 · 2023